Kevin M. Marks

8.2k total citations · 1 hit paper
14 papers, 4.2k citations indexed

About

Kevin M. Marks is a scholar working on Molecular Biology, Cancer Research and Genetics. According to data from OpenAlex, Kevin M. Marks has authored 14 papers receiving a total of 4.2k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 4 papers in Cancer Research and 2 papers in Genetics. Recurrent topics in Kevin M. Marks's work include Epigenetics and DNA Methylation (5 papers), Cancer-related gene regulation (4 papers) and Cancer, Hypoxia, and Metabolism (3 papers). Kevin M. Marks is often cited by papers focused on Epigenetics and DNA Methylation (5 papers), Cancer-related gene regulation (4 papers) and Cancer, Hypoxia, and Metabolism (3 papers). Kevin M. Marks collaborates with scholars based in United States, Japan and Canada. Kevin M. Marks's co-authors include Stefan Größ, Katharine Yen, Valeria R. Fantin, Marie C. Keenan, Edward M. Driggers, Patrick S. Ward, Lenny Dang, David W. White, Mark Bittinger and Matthew G. Vander Heiden and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Blood.

In The Last Decade

Kevin M. Marks

14 papers receiving 4.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

2009 3.1k citations Lenny Dang, David W. White et al. Nature profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kevin M. Marks United States	9	2.6k	1.8k	1.3k	454	417	14	4.2k
Marie C. Keenan United States	6	2.6k 1.0×	2.0k 1.1×	1.3k 1.0×	401 0.9×	414 1.0×	8	4.1k
Stefan Größ United States	17	3.5k 1.3×	2.8k 1.6×	1.8k 1.4×	570 1.3×	691 1.7×	27	5.5k
Mark Bittinger United States	14	2.8k 1.1×	2.1k 1.2×	1.5k 1.2×	587 1.3×	594 1.4×	20	4.6k
Shengfang Jin United States	16	3.9k 1.5×	2.5k 1.4×	1.7k 1.3×	766 1.7×	785 1.9×	21	5.8k
Ivan Kos Croatia	11	2.0k 0.8×	1.9k 1.0×	2.8k 2.1×	485 1.1×	195 0.5×	24	4.7k
David R. Wise United States	15	4.3k 1.6×	3.8k 2.1×	648 0.5×	799 1.8×	559 1.3×	48	6.3k
Katharine Yen United States	22	3.6k 1.4×	2.8k 1.6×	2.1k 1.6×	662 1.5×	1.2k 3.0×	38	5.9k
Shinsan M. Su United States	13	4.4k 1.7×	3.5k 1.9×	2.4k 1.8×	658 1.4×	1.4k 3.3×	16	6.9k
Russell O. Pieper United States	44	3.9k 1.5×	1.7k 0.9×	1.9k 1.5×	2.1k 4.6×	179 0.4×	105	6.7k
Lenny Dang United States	26	5.0k 1.9×	3.7k 2.1×	2.3k 1.7×	1.5k 3.3×	1.4k 3.2×	50	8.3k

Countries citing papers authored by Kevin M. Marks

Since Specialization

Citations

This map shows the geographic impact of Kevin M. Marks's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kevin M. Marks with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kevin M. Marks more than expected).

Fields of papers citing papers by Kevin M. Marks

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kevin M. Marks. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kevin M. Marks. The network helps show where Kevin M. Marks may publish in the future.

Co-authorship network of co-authors of Kevin M. Marks

This figure shows the co-authorship network connecting the top 25 collaborators of Kevin M. Marks. A scholar is included among the top collaborators of Kevin M. Marks based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kevin M. Marks. Kevin M. Marks is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Hyer, Marc L., Peter Kalev, Mark P. Fletcher, et al.. (2020). Abstract 3090: The MAT2A inhibitor, AG-270, combines with both taxanes and gemcitabine to yield enhanced anti-tumor activity in patient-derived xenograft models. Cancer Research. 80(16_Supplement). 3090–3090. 3 indexed citations

Marjon, Katya, Peter Kalev, & Kevin M. Marks. (2020). Cancer Dependencies: PRMT5 and MAT2A in MTAP/p16-Deleted Cancers. 5(1). 371–390. 17 indexed citations

Heist, Rebecca S., Mrinal M. Gounder, Sophie Postel‐Vinay, et al.. (2019). Abstract PR03: A phase 1 trial of AG-270 in patients with advanced solid tumors or lymphoma with homozygous MTAP deletion. Molecular Cancer Therapeutics. 18(12_Supplement). PR03–PR03. 5 indexed citations

Marjon, Katya, Peter Kalev, Marc L. Hyer, et al.. (2019). Abstract 2714: Targeting MAT2A in CDKN2A/MTAP-deleted cancers. Cancer Research. 79(13_Supplement). 2714–2714. 1 indexed citations

Ulanet, Danielle, Victor Chubukov, Mya Steadman, et al.. (2019). Hematologic Malignancies Exhibit Selective Vulnerability to Inhibition of De Novo Pyrimidine Biosynthesis By AG-636, a Novel Inhibitor of Dihydroorotate Dehydrogenase in Phase 1 Clinical Trials. Blood. 134(Supplement_1). 1570–1570. 2 indexed citations

Marjon, Katya, Michael J. Cameron, Phong Quang, et al.. (2016). MTAP Deletions in Cancer Create Vulnerability to Targeting of the MAT2A/PRMT5/RIOK1 Axis. Cell Reports. 15(3). 574–587. 280 indexed citations

Marks, Kevin M., Eun Sun Park, Alexander Arefolov, et al.. (2011). The Selectivity of Austocystin D Arises from Cell-Line-Specific Drug Activation by Cytochrome P450 Enzymes. Journal of Natural Products. 74(4). 567–573. 34 indexed citations

Fantin, Valeria R., Lenny Dang, David W. White, et al.. (2010). Abstract 33: Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Cancer Research. 70(8_Supplement). 33–33. 4 indexed citations

Dang, Lenny, David W. White, Stefan Größ, et al.. (2010). Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 465(7300). 966–966. 399 indexed citations

10.

Dang, Lenny, David W. White, Stefan Größ, et al.. (2009). Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 462(7274). 739–744. 3067 indexed citations breakdown →

11.

Marks, Kevin M. & Garry P. Nolan. (2006). Chemical labeling strategies for cell biology. Nature Methods. 3(8). 591–596. 200 indexed citations

12.

Marks, Kevin M., et al.. (2004). In Vivo Targeting of Organic Calcium Sensors via Genetically Selected Peptides. Chemistry & Biology. 11(3). 347–356. 62 indexed citations

13.

Marks, Kevin M., Patrick D. Braun, & Garry P. Nolan. (2004). A general approach for chemical labeling and rapid, spatially controlled protein inactivation. Proceedings of the National Academy of Sciences. 101(27). 9982–9987. 83 indexed citations

14.

Yen, Andrew, Van Cherington, Brian Schaffhausen, Kevin M. Marks, & Susi Varvayanis. (1999). Transformation-Defective Polyoma Middle T Antigen Mutants Defective in PLCγ, PI-3, or src Kinase Activation Enhance ERK2 Activation and Promote Retinoic Acid-Induced, Cell Differentiation Like Wild-Type Middle T. Experimental Cell Research. 248(2). 538–551. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact